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Mutations in INPP5K Cause a Form of
Congenital Muscular Dystrophy Overlapping
Marinesco-Sjo¨gren Syndrome and Dystroglycanopathy
Daniel P.S. Osborn,1 Heather L. Pond,2 Neda Mazaheri,3,4 Jeremy Dejardin,1 Christopher J. Munn,5
Khaloob Mushref,2 Edmund S. Cauley,2 Isabella Moroni,6 Maria Barbara Pasanisi,6,7 Elizabeth A. Sellars,8
R. Sean Hill,9,10 Jennifer N. Partlow,9,10 Rebecca K. Willaert,11 Jaipreet Bharj,1 Reza Azizi Malamiri,12
Hamid Galehdari,3,4 Gholamreza Shariati,4,13 Reza Maroofian,1,14 Marina Mora,7 Laura E. Swan,5
Thomas Voit,15 Francesco J. Conti,15 Yalda Jamshidi,1,16,* and M. Chiara Manzini2,16,*
Congenital muscular dystrophies display a wide phenotypic and genetic heterogeneity. The combination of clinical, biochemical, and
molecular genetic findings must be considered to obtain the precise diagnosis and provide appropriate genetic counselling. Here we
report five individuals from four families presenting with variable clinical features including muscular dystrophy with a reduction in
dystroglycan glycosylation, short stature, intellectual disability, and cataracts, overlapping both the dystroglycanopathies and Marine-
sco-Sjo¨gren syndrome. Whole-exome sequencing revealed homozygous missense and compound heterozygous mutations in INPP5K in
the affected members of each family. INPP5K encodes the inositol polyphosphate-5-phosphatase K, also known as SKIP (skeletal muscle
and kidney enriched inositol phosphatase), which is highly expressed in the brain andmuscle. INPP5K localizes to both the endoplasmic
reticulum and to actin ruffles in the cytoplasm. It has been shown to regulate myoblast differentiation and has also been implicated in
protein processing through its interaction with the ER chaperone HSPA5/BiP. We show that morpholino-mediated inpp5k loss of func-
tion in the zebrafish results in shortened body axis, microphthalmia with disorganized lens, microcephaly, reduced touch-evoked
motility, and highly disorganized myofibers. Altogether these data demonstrate that mutations in INPP5K cause a congenital muscular
dystrophy syndrome with short stature, cataracts, and intellectual disability.Congenital muscular dystrophy (CMD) encompasses a
group of disorders characterized by muscle weakness and
progressive loss of muscle mass and function, presenting
at birth or infancy.1,2 Multiple forms of CMDs are also asso-
ciated with cerebral and ocular phenotypes, suggesting
common mechanisms affecting development of the mus-
cle, brain, and eye. For these syndromic forms, gene iden-
tification studies have primarily pointed to a molecular
mechanism involving interactions between cells and
the surrounding extracellular matrix (ECM).3 Mutations
in up to 19 glycosyltransferases and accessory proteins
involved in the glycosylation of the transmembrane glyco-
protein dystroglycan (DAG1 [MIM:128239]) lead to a spec-
trum of CMDs termed dystroglycanopathies.4,5 Dystrogly-
canopathy-associated genes function in the endoplasmic
reticulum (ER) and/or Golgi apparatus to regulate dystro-
glycan glycosylation. Genetic and function studies have
shown that glycans are critical to control normal tissue
development in the brain, eye, and muscle, via interac-1Cardiovascular and Cell Sciences Institute, St George’s University of London, C
Physiology, The George Washington University School of Medicine and Healt
Chamran University of Ahvaz, Ahvaz 6135783151, Iran; 4Narges Medical Gen
6155689467, Iran; 5Department of Cellular and Molecular Physiology, Institute
6Pediatric Neurology Unit, Fondazione IRCCS Istituto Neurologico C. Besta, 20
ogy, Fondazione IRCCS Istituto Neurologico C. Besta, 20126 Milan, Italy; 8De
Arkansas for Medical Sciences, Arkansas Children’s Hospital, Little Rock, AR 72
Boston, MA 02115, USA; 10Howard Hughes Medical Institute, Boston Children
USA; 12Department of Paediatric Neurology, GolestanMedical, Educational, an
6163764648, Iran; 13Department of Medical Genetics, Faculty of Medicine, Ah
14University of Exeter Medical School, RILD Wellcome Wolfson Centre, Royal
Biomedical Research Centre, Great Ormond Street Institute of Child Health, U
16These authors contributed equally to this work
*Correspondence: yjamshid@sgul.ac.uk (Y.J.), cmanzini@gwu.edu (M.C.M.)
http://dx.doi.org/10.1016/j.ajhg.2017.01.019.
The Ameri
 2017 The Author(s). This is an open access article under the CC BY-NC-NDtions with the ECM.5 The most severe forms of dystrogly-
canopathy present with CMD associated with lissence-
phaly (smooth brain) and a variety of eye malformations
affecting both the retina and the anterior chamber (e.g.,
cataracts, glaucoma), but multiple case subjects have
only CMD with intellectual disability and more subtle
brain findings.6,7
Marinesco-Sjo¨gren syndrome (MSS [MIM:248800]) is a
form of myopathy with a similar constellation of findings
including muscle involvement, intellectual disability, cata-
racts, brain MRI findings, and other signs of central ner-
vous system (CNS) involvement.8,9 Cerebellar atrophy is
often considered the most prominent neuroradiologic
finding in MSS, but it is not an obligatory finding.10 The
clinical overlap can therefore make it difficult to distin-
guish between syndromic CMDs and MSS. MSS is also
considered to be a clinically and genetically heterogeneous
disorder with approximately 70% of MSS-affected case
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Figure 1. Mutations in INPP5K Severely
Disrupt Protein Function
(A) Pedigrees of families 1 to 4 where five
autosomal-recessive alleles in INPP5K
havebeen identifiedby exome sequencing.
(B) Four missense mutations are localized
to the phosphatase domain in INPP5K,
while a C-terminal frameshift affects the
last actin ruffle targeting domain.
(C) Protein conservation in the four
INPP5K amino acids altered by the identi-
fiedmissensemutations. Percent conserva-
tion (cons) to the human gene is shown
and asterisk (*) indicates conservation
across all species listed.
(D) Phosphatase activity was measured by
using malachite green dye to detect GST-
INPP5K-mediated phosphate release in
the presence of the soluble lipid substrate
PI(4,5)P2 diC8, showing that all reported
mutations compromise the enzymatic ac-
tivity of INPP5K. Results of three indepen-
dent experiments were presented as
mean 5 standard deviation. See Table 1
for numeric values.SIL1 acts as a nucleotide exchange factor for heat shock
protein family A member 5 (HSPA5) (also known as
GRP78 [glucose-related protein 78] or BiP [immunoglob-
ulin binding protein]), an essential regulator of ER func-
tion; the identification of these mutations has led to the
suggestion that MSS is a disorder of protein biosynthesis
or processing in the ER.11
In this report, we present five individuals from four
families diagnosed with a syndrome overlapping both
the dystroglycanopathy and the MSS spectrum with reces-
sive mutations in inositol polyphosphate-5-phosphatase
K (INPP5K [MIM:607875]) (Figure 1). INPP5K belongs to
a family of phosphatidylinositol (PI) phosphatases respon-
sible for removing the phosphate on position 5 of the
inositol ring leading to PI(3,4)P2 from PI(3,4,5)P3 and
PI4P from PI(4,5)P2. Also known as skeletal muscle and kid-
ney-enriched inositol phosphatase (SKIP), INPP5K is highly
expressed in the developing and adult brain, eye, and mus-
cle.12–14 It is primarily localized to the ER, and it can form a
complex with HSPA5/BiP to regulate insulin receptor
signaling at actin ruffles on the plasma membrane by
acting as a negative regulator of phosphatidylinositol-3-ki-538 The American Journal of Human Genetics 100, 537–545, March 2, 2017nase (PI3K) signaling,15 suggesting a
possible overlap with the function of
the MSS-associated gene SIL1.
In agreement with the Declaration
of Helsinki, informed consent for ge-
netic and biochemical studies was ob-
tained from all study participants or
their guardians under the authority
of the George Washington University
Internal Review Board and the Narges
Medical Genetics and Prenatal Diag-
nosis Laboratory. Subjects 1.1 and1.2 (S1.1 and S1.2; Figure 1A, Table 1) are two affected sis-
ters (7 and 13 years old) born of an Arabian consanguin-
eous family in Iran, who were initially diagnosed with
muscle atrophy and global developmental delay. Both
were born without complications, and early development
was normal with the exception of delayed walking from
18 months after a period of occupational therapy. Both sis-
ters experienced febrile seizures in infancy (9 months) and
early childhood (2 years), and routine interictal electroen-
cephalography in the elder sister was normal. They dis-
played difficulty rising from a squatting position, impaired
toe-standing, and unsteady gait. At the age of 2 years the
elder sister began to show hypotonicity that progressed
to spasticity including diffuse loss of muscle bulk, exagger-
ated deep tendon reflexes, positive pyramidal signs, and
fatty infiltration resulting in frequent falls, toe walking,
spastic gait, and pronounced hyperlordosis. Neither sister
can climb stairs without support. After orthopedic surgery,
the elder sister uses a wheelchair and muscle biopsy
showed myogenic atrophy. Electromyogram (EMG) report
also showed the presence of myopathy involving both her
lower limbs, with more involvement of the proximal
Table 1. Clinical Features of Individuals with Biallelic INPP5K Mutations
Subject S1.1 S1.2 S2 S3 S4
Protein change p.Met93Val p.Met93Val p.Val23Met; p.Asp269Asn p.Val23Met p.Gly140Ser;
p.Asn417Lysfs*26
% WT function 42%5 9% 42% 5 9% 27% 5 7%; 10% 5 8% 27% 5 7% 13% 5 1%; 58%5 10%
Ethnic origin Iranian-Arab Iranian-Arab Italian Italian European American
Sex F F F M F
Current age 13 y 7 y 31 y 21 y 17 y
Short stature þ þ þ þ þ
Cataracts  þ þ  þ
Strabismus þ þ   þ
Spine hyperlordosis þ þ  þ 
Muscle weakness þ þ þ þ þ
CK 1,041 U/L 1,184 U/L elevated >1,000 U/L elevated
EMG myopathic changes NA myopathic changes myopathic changes NA
Muscle biopsy myogenic atrophy NA dystrophic; reduced a-DG dystrophic; reduced a-DG NA
Spasticity þ þ þ/  þ
Mobility wheelchair-bound assisted walking wheelchair-bound wheelchair-bound ambulatory
Intellectual disability moderate/severe moderate/severe moderate/severe moderate moderate
Seizures þ þ þ  
Microcephaly borderline þ  þ þ
MRI normal NA brain atrophy normal normal
Abbreviations are as follows: WT, wild type; y, years; NA, not assessed; a-DG, a-dystroglycan.muscles. Both sisters have increased serum creatine kinase
(CK), aldolase, and alkaline phosphatase levels. They have
moderate to severe intellectual disability (ID), both
attending special schools. Brain magnetic resonance imag-
ing (MRI) of S1.1 was normal at the ages of 8 and 13. Both
sisters have short stature, microcephaly, and impaired
speech. Variable clinical features include bilateral cataracts
in S1.2.
Whole-exome sequencing (see Table S1 for details) was
performed on S1.1, focusing on the identification of
potentially deleterious rare homozygous variants due to
the presence of multiple large regions of homozygosity.
Thirteen candidate genes were identified with homozy-
gous missense mutations (Table S2). A homozygous
variant in INPP5K (GenBank: NM_016532; Table S3) was
identified within an 8-Mb region of homozygosity
(c.277A>G [p.Met93Val]) (Figures 1A and 1B). Sanger
sequencing confirmed that both affected children were
homozygous for this variant and each parent was hetero-
zygous for the variant. The variant is unique in an in-
house dataset of 450 geographically matched individuals
sequenced by exome and is not represented in the Greater
Middle Eastern Variome,16 in 60,706 individuals in the
Exome Aggregation Consortium (ExAC) Browser,17 or in
141,353 individuals in the Genome Aggregation Database
(gnomAD). This mutation affects a highly conservedThe Ameriresidue (Figure 1C) and is predicted to be pathogenic by
multiple prediction tools (SIFT ¼ 0.01; CADD ¼ 22.7)18
(Table S3).
Subjects 2 (S2) and 3 (S3) were simplex cases originating
from southern Italy. S2 (Figure 1A, Table 1) is 31 years old
and was referred with a diagnosis of CMD as a child. She
was born at term with low birth weight and presented
with motor and cognitive delay since early infancy. At 2
years of age, she underwent surgery for bilateral cataracts.
Upon neuromuscular examination at age 5, she was
able to walk independently, but her upper limbs were hy-
potonic and hypotrophic with no tendon reflexes and
her lower limbs were slightly hypertonic with brisk tendon
reflexes. CK and aldolase levels were reported as higher
than normal. EMG revealed myopathic changes with
normal sensory and motor conduction velocities. A biopsy
of the quadriceps muscle showed neuromyogenic changes.
Fiber diameter was variable, with several small rounded
or wedge-shaped fibers, mildly increased perymisial
connective tissue, rare centrally located nuclei, and a
few degenerating and regenerating fibers (H&E stain-
ing, Figure 2A). a-dystroglycan immunohistochemistry
using either the VIA4-1 or IIH6 antibody (Millipore)
showed reduced protein glycosylation on fiber surfaces
(Figure 2C). Dystrophin-associated glycoproteins and lam-
inin-a2 were normally expressed (not shown). In additioncan Journal of Human Genetics 100, 537–545, March 2, 2017 539
Figure 2. Muscular Dystrophy and Loss
of Dystroglycan Glycosylation in Subjects
S2 and S3
(A and B) Haematoxylin and eosin (H&E)
staining (A) from normal control subject
(con) and subject S2 and Gomori tri-
chrome staining (B) from control (con)
and subject S3. Both biopsies show great fi-
ber size variability, and increased perimy-
sial connective tissue and regenerating
fibers are indicated by arrows in S2. Scale
bar represents 100 mm.
(C) Immunostaining of a-dystroglycan
glycosylation in muscle biopsies from S2
and S3, showing reduced and irregular pro-
tein expression in the affected individuals
compared to the control subject (con).
Scale bar represents 50 mm.to the neuromuscular phenotype, she presented with dys-
morphic features: short stature, thin hair, globular nose,
and micrognathism, plus skeletal anomalies such as 13
ribs and scoliosis. A cerebral CT showed an elongated (doli-
chocephalic) skull, with underdevelopment of both cortex
and white matter of cerebral hemispheres. She was treated
for focal seizures until she was 10 years old. A brain MRI,
performed at age 18 years, showed an anomaly of the cra-
niovertebral junction (odontoid process in the foramen
magnum) and enlarged lateral ventricles and subarachnoid
spaces, suggesting progressive brain atrophy. During
follow-ups, the subject’s clinical features remained stable.
She presents with moderate-severe ID without speech def-
icits and is very sociable. At 22 years of age she could still
walk independently, but needed handrail support when
going up and down stairs. Strength evaluation showed
moderate proximal weakness of upper limbs and moder-
ate-severe proximal and distal weakness of lower limbs
with initial retractions of adductor muscles and Achilles
tendons. Due to a fall resulting in a femur fracture at
age 28, she is now wheelchair-bound.
S3 (Figure 1A, Table 1) is a 21-year-old male who also
presented with delayed psychomotor development at
23 months after an uneventful pregnancy and delivery.
Neurological examination at 3 years of age identified
marked axial and limb hypotonia with proximal upper
and lower limb weakness, marked lumbar hyperlordosis,
and areflexia. Gower’s sign was positive. CK was elevated
often above 1,000 U/L and muscle biopsy showed neuro-
myogenic changes. A mild increase of perimysial connec-
tive tissue was noted with variable fiber size with hyper-,
hypo-, and atrophic fibers, a few centrally located nuclei,
split fibers, rare degenerating fibers, and small type group-
ings (Gomori trichrome staining, Figure 2B). a-dystrogly-
can immunohistochemistry showed reduced glycosylation
expression on fiber surfaces (Figure 2C), while dystrophin,
dystrophin-associated glycoproteins, and laminin-a2 were
normally expressed. He was moderately dysmorphic
with an elongated face. Mild ID and microcephaly were
noted, but brainMRI was normal. During subsequent years540 The American Journal of Human Genetics 100, 537–545, Marchmuscle weakness slowly worsened with loss of autono-
mous gait at age 12. No cardiac impairment was noticed
at echocardiographic examinations, while a mild restric-
tive respiratory deficiency was noticed since adolescence.
No eye involvement was reported until the last visit at
age 21.
S2 and S3 underwent exome sequencing as part of a
cohort of Italian case subjectswithCMDwithvariable brain
abnormalities and cognitive deficits (see Table S1 for details
on exome). Exomes were filtered using custom SQL queries
for rare (<0.5% frequency in the ExAC Browser for both
total and non-Finnish European populations) and likely
pathogenic (missense, splicing, or truncating) variants.19
Remaining variants were visually analyzed on the Integra-
tive Genomics Viewer (IGV),20 leading to three candidate
genes in S2 and three candidates in S3 (Table S2). Both indi-
viduals had biallelic missense variants in INPP5K (Figures
1A and 1B). S2 carries compound heterozygous transitions
c.67G>A (p.Val23Met) and c.805G>A (p.Asp269Asn),
while S3 is homozygous for c.67G>A (Table S3). Both vari-
ants affect conserved residues (Figure 1C), found in less
than 1:100,000 alleles in the ExAC and gnomAD browsers
and are predicted to be pathogenic (p.Val23Met: SIFT ¼ 0;
PolyPhen2 ¼ 1; CADD ¼ 16.7; p.Asp269Asn: SIFT ¼ 0;
PolyPhen2 ¼ 1; CADD ¼ 34) (Table S3).
Finally, subject 4 (S4, Figure 1A, Table 1) originated
from the United States and was referred to us via
GeneMatcher21,22 after clinical exome sequencing in the
trio (proband and parents). She is a 17-year-old female
who presented in early childhood with delay in reaching
motor and cognitive developmental milestones. She
walked independently at 18 months. She did not babble
until age 3 and had phrases at age 4. Bilateral cataracts
were identified at 2 years of age and surgically corrected.
Since childhood she had upper and lower limb hypotonia,
leading to balance problems and frequent falls. CK is
elevated above 1,000. Currently, she has an appreciable
loss of muscle mass in her hands and feet. She toe walks
and fatigues easily. EMG at 16 years of age was normal.
A muscle biopsy has not been performed. She has short2, 2017
stature for which she was treated with growth hormone.
Other findings include hirsutism, microcephaly, and
moderate ID. Brain MRI at age 16 was normal. Clinical
exome sequencing was performed by GeneDX using
proprietary capture chemistry (Table S1 for details).
Further analysis identified INPP5K as the gene most likely
to harbor the responsible pathogenic variants. S4 carries a
likely pathogenic transition and a small deletion in com-
pound heterozygosity, c.418G>A (p.Gly140Ser; SIFT ¼ 0;
PolyPhen2 ¼ 1; CADD ¼ 28.6) and c.1251_1252delCA
(p.Asn417Lysfs*26) (Figures 1A and 1B). The missense
variant alters a conserved residue and is extremely rare;
the deletion is not found in ExAC and gnomAD browsers
(Table S3).
In summary, all individuals with likely pathogenic
biallelic mutations in INPP5K present with myopathic
findings and elevated CK, short stature, motor and cogni-
tive developmental delay since early infancy, and moder-
ate-severe ID. Cataracts were present in S1.1, S2, and S4,
but not S1.1’s sibling S1.2, showing variability even within
the same family. While no ataxia or cerebellar atrophy was
noted, this presentation is reminiscent of MSS and could
fall in the larger MSS spectrum.23 In addition, a reduction
in dystroglycan glycosylation in S2 and S3 suggest an over-
lap with less severe forms of dystroglycanopathies, where
CMD is present with cataracts and ID.6,7 Similar cases of
merosin-positive CMD with cataracts and ID have been
previously reported,24,25 also suggesting that this disorder
may represent a distinct clinical entity.
Since the identified variants are either missense or late
truncations, we sought to determine their impact on pro-
tein function by performing phosphatase activity assays.
GST-tagged full-length INPP5K constructs (wild-type and
mutants) were assayed for their activity against 135 mM
PtdIns(4,5)P2diC8 soluble lipid substrate in phosphatase
assay buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl,
10 mM MgCl2). Free phosphate was measured using the
malachite green assay kit (Echelon Biosciences) and cali-
brated against standards according to the manufacturer’s
instructions. To minimize variability between purifica-
tions, all constructs were freshly prepared and purified in
parallel for each experiment, and beads used in the assay
were afterward run on Coomassie gels to confirm equal
protein loading. We found that when compared to a phos-
phatase-dead construct (p.Asp310Gly), p.Gly140Ser and
p.Asp269Asn had almost no enzymatic activity, while
p.Val23Met and p.Met93Val retained 27% and 42% activ-
ity, respectively. The C-terminal frameshift deletion
p.Asn417Lysfs*26, which is located outside of the phos-
phatase domain, was the least severely disrupted (57% ac-
tivity in this assay) (Figure 1D). Both S1.1/2 and S3 are
homozygous for variants that only partially reduce phos-
phatase activity of INPP5K, but analysis of more case sub-
jects will be necessary to establish genotype/phenotype
correlation.
To explore the role of INPP5K during early development,
we targeted inpp5k in the zebrafish embryo using antisenseThe Amerimorpholino oligonucleotides (MOs, GeneTools, LLC).
Teleost fish underwent a genome duplication event, lead-
ing to approximately 30% of genes having a paralog.26
inpp5k is present in two copies in the zebrafish genome:
inpp5ka and inpp5kb. Alignment of both homologs indi-
cate that inpp5ka is more similar to INPP5K (Figure S1), sug-
gesting that it is the closest ortholog of the human gene. In
addition, quantitative PCR expression analysis in the
zebrafish embryo indicated that inpp5ka expression is,
respectively, 7-fold and 16-fold higher than inpp5kb at
1 and 2 days post fertilization (dpf) (Figure S1B). MOs
were designed by two independent groups to target both
the start site (translation-blocking) and splicing of the
inpp5ka and bmRNA, leading to four independent MOs be-
ing tested for each gene (Table S4, Figures 3 and S2–S4). Ex-
periments were also performed on two independent
strains, TupLF and AB.
Injections of inpp5ka MOs in the fertilized oocyte re-
sulted in a striking phenotype in zebrafish embryos and
larvae, which featured microphthalmia, microcephaly,
curved and shortened body, and reduced touch-evoked
motility (Figures 3A and S2–S4, Movies S1, S2, S3, S4,
and S5). This phenotype was consistent across all inpp5ka
MOs injections and in the inpp5ka and b doublemorphant,
while inpp5kb MOs alone showed very mild phenotypes
(Figures S2A–S2D and S4). It is not uncommon for one
gene in a pair of duplicated orthologs to lose its function
or be silenced.27 Therefore, all subsequent analysis was per-
formed on inpp5ka morphants to reduce as much as
possible the amount of MO injected in the embryos and
avoid non-specific effects. inpp5ka morphant phenotypes
could be significantly improved by co-injection of 200 pg
of capped human INPP5K mRNA, while injection of
INPP5K mRNA alone had no effect (Figures S2E and S2F).
Examination of the eye by wax sectioning followed by
H&E staining showed that in morphants eyes are orien-
tated downward, as indicated by the position of the lens
(Figure 3B). At 3 dpf the lens organizes in a cellular cortex
and an acellular nucleus.28 a-crystallin (zl-1; Zebrafish In-
ternational Resource Center) immunostaining in axial sec-
tions of the inpp5kamorphant showed that the lens cortex
was disorganized and cell nuclei were present in the center
of the lens nucleus, leading to a phenotype reminiscent of
congenital cataracts (Figure 3C).
A birefringence assay using polarized light to image the
densely packed and highly organized nature of muscle
fibers of control embryos showed that knockdown of
inpp5ka caused a substantial reduction in birefringence
(Figure 3D), suggesting muscle fiber disorganization. To
better evaluate skeletal muscle structure, phalloidin
(Molecular Probes) was used to mark filamentous actin
(F-actin) in sarcomeres. Control embryos display densely
packed, organized muscle fibers in the trunk of the zebra-
fish embryo (Figure 3E). inpp5ka morphants showed
sparser, disorganized myofibers, with the appearance of
‘‘wavy fibers’’ (Figure 3E). As the role of INPP5K has not
been previously characterized, we investigated its potentialcan Journal of Human Genetics 100, 537–545, March 2, 2017 541
Figure 3. Knockdown of inpp5ka in Zebrafish Causes Defective Eye Development and Muscle Formation
(A) General morphological abnormalities were observed in inpp5kamorphant embryos at 4 dpf, compared to control morpholino (MO)
or uninjected control age-matched embryos. Scale bar represents 500 mm.
(B) Aberrant eye development was observed in inpp5kamorphant wax sections stained with H&E; eyes were observed reduced in size and
downwardly oriented. Scale bar represents 200 mm.
(C) Structural analysis of the lens, by staining for a-crystallin, identifies disorganization in inpp5ka morphant embryos. In addition,
abnormal medial nuclei retention was observed in inpp5kamorphant lens, as marked by DNA stain Hoechst. Scale bar represents 50 mm.
(D) Birefringence of inpp5kamorphant embryos reveals decreased muscle integrity compared to uninjected or control MO-injected em-
bryos at 4 dpf. Scale bar represents 200 mm.
(E) Analysis of muscle fiber and neuromuscular junction formation using Phalloidin (Red, F-actin) and alpha-Bungarotoxin
(Green, AChR), respectively, reveals misaligned myofibers and reduced NMJ arborization in morphants. Scale bar represents 100 mm.role in the formation of neuromuscular junctions (NMJs).
Analysis of NMJs, by targeting the acetylcholine receptors
(AChR) using the high-affinity fluorophore-conjugated
alpha-Bungarotoxin (Molecular Probes), reveals reduced
synaptic formation in the skeletal muscle of inpp5ka
knockdown embryos (Figure 3E). Thus, inpp5ka is required
for appropriate formation of skeletal muscles and NMJs.
Finally, transmission electron microscopy (TEM) was
used to expose sarcomeric assembly defects consistent
with reduced motility in the morphants (Figure 4A). While
control embryos display clearly defined electron dense
anisotropic (A-bands) and less dense isotropic (I-bands)
bands, the morphants have undefined A- and I-bands
(Figure 4B). Sarcomere length is shorter in inpp5ka knock-
down embryos, compared to control MO-injected or unin-
jected embryos, a phenotype normally associated with
contracted sarcomeres. In addition, myofibrils are loosely
packed with a disorganized arrangement in morphants.542 The American Journal of Human Genetics 100, 537–545, MarchTriads, consisting of T-tubules and sarcoplasmic reticulum
(SR), are required for sarcomeric contraction. Knockdown
of inpp5ka results in triads that are on average half the
size of those in control embryos (Figures 4C–4E), a possible
feature of an exhausted SR.29 Muscular dystrophy pheno-
types are associated with detachment of myofibers at
somite borders.30 We analyzed muscle fiber attachment
at the somite borders in knockdown and control embryos
(Figure 4C). Control embryos showed well-defined
attachments to the myoseptum, which were reduced in
morphant embryos. Muscle fiber detachments were not
observed in the F-actin immunofluorescent staining,
suggesting that although the myoseptal attachments are
present, they may be weaker. Taken together, these data
suggest that inpp5ka is required for appropriate sarcomere
assembly and function.
In summary, we identified five independent alleles in
INPP5K leading to a disorder characterized by short2, 2017
Figure 4. Zebrafish Loss of inpp5ka Results in Disorganized Myofibrils and Insufficient Sarcomere Assembly, as Analyzed by Trans-
mission Electron Microscopy
(A) Assessment of sarcomere assembly at the ultrastructural level shows less compact myobrils, short sarcomere length, and undefined
regional divisions. Scale bar represents 2 mm.
(B) High-magnification image of sarcomere assembly indicates the loss of defined anisotropic (black bracket) and isotropic (blue bracket)
bands in morphant embryos. T-tubules are also notably smaller than control embryos (arrows). Scale bar represents 2 mm.
(C) Muscle fiber attachments at the somite borders presented disorganized and weak unions with the myoseptum in morphants em-
bryos. Scale bar represents 1 mm.
(D) Top panel shows a schematic diagram of the Triad assembly, composed of the sarcoplasmic reticulum (SR) and T-tubule (T) sand-
wiched between muscle fibers (MF). Middle and lower panels show representative triad morphology for control and inpp5kamorphant
fish, respectively.
(E) Triad size was quantified using the combined area of SR and T per triad. Con 58.2 5 SEM 7.254; n ¼ 10, inpp5kaMO 28.3 5 SEM
2.371; n ¼ 10. **p% 0.01, as analyzed by an unpaired t test.stature, ID, CMD, and cataracts. inpp5k loss-of-function
modeling in the zebrafish led to a constellation of pheno-
types that closely resembles the human presentation,
including reduced growth, microcephaly, lens disorgani-
zation, reduced motility, and myopathy. The clinical pre-
sentation partially overlaps with MSS, and with at least
two subjects showing a reduction in dystroglycan glyco-
sylation, suggests a continuum with the dystroglycanopa-
thies. This combination of phenotypes could be explained
both by INPP5K enzymatic function and by its binding
partners in the ER. Because of its role in converting
PIP2, INPP5K has been shown to promote myoblast differ-
entiation by controlling the myogenic loop triggered by
insulin-growth factor II (IGF-II) through the PI3K-AKT-
mTOR pathway.31 Little is known about the role of
INPP5K in the brain, but IGF-II activity is also critical
for learning and memory consolidation.32 It is possible
that changes in AKT-mTOR activity in the brain will
contribute to cognitive deficits as this signaling pathway
has been found disrupted in multiple neurodevelopmen-
tal disorders.33 In addition, INPP5K’s signaling activity is
directly regulated by its binding partner HSPA5/BiP,15,34
which is in turn regulated by the MSS-associated gene
SIL1.11 SIL1 regulates the activation stage of HSPA5/BiP
in the ER and BiP is a critical chaperone for trafficking
of glycoproteins.11 Therefore, INPP5K could alter dystro-
glycan targeting by altering HSPA5/BiP function. Future
studies must address the role of INPP5K in signaling regu-
lation and glycoprotein trafficking during brain and mus-
cle development.The AmeriSupplemental Data
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